These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18709023)

  • 1. Blocking of angiotensin II is more than blocking of transforming growth factor-beta.
    Daniel C
    Kidney Int; 2008 Sep; 74(5):551-3. PubMed ID: 18709023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation.
    Carvajal G; Rodríguez-Vita J; Rodrigues-Díez R; Sánchez-López E; Rupérez M; Cartier C; Esteban V; Ortiz A; Egido J; Mezzano SA; Ruiz-Ortega M
    Kidney Int; 2008 Sep; 74(5):585-95. PubMed ID: 18509316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-beta and Smad signalling in kidney diseases.
    Wang W; Koka V; Lan HY
    Nephrology (Carlton); 2005 Feb; 10(1):48-56. PubMed ID: 15705182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition.
    Yang J; Dai C; Liu Y
    J Am Soc Nephrol; 2005 Jan; 16(1):68-78. PubMed ID: 15537870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorofenidone suppresses epithelial-mesenchymal transition and the expression of connective tissue growth factor via inhibiting TGF-beta/Smads signaling in human proximal tubular epithelial cells.
    Yuan Q; Wang L; Zhang F; Wang R; Fu X; Peng Z; Ning W; Hu G; Wang Z; Tao L
    Pharmazie; 2011 Dec; 66(12):961-7. PubMed ID: 22312703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis?
    Ketteler M; Noble NA; Border WA
    Annu Rev Physiol; 1995; 57():279-95. PubMed ID: 7778869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway.
    Wolf G
    Kidney Int; 2006 Dec; 70(11):1914-9. PubMed ID: 16985515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-beta in renal injury and disease.
    Böttinger EP
    Semin Nephrol; 2007 May; 27(3):309-20. PubMed ID: 17533008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target?
    Noble NA; Border WA
    Semin Nephrol; 1997 Sep; 17(5):455-66. PubMed ID: 9316214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis.
    Border WA; Noble NA
    Hypertension; 1998 Jan; 31(1 Pt 2):181-8. PubMed ID: 9453300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-beta in human glomerular injury.
    Peters H; Noble NA; Border WA
    Curr Opin Nephrol Hypertens; 1997 Jul; 6(4):389-93. PubMed ID: 9263690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin suppresses epithelial to mesenchymal transition and intercepts Smad signal transduction through a MEK-dependent mechanism in pig kidney (LLC-PK1) cell lines.
    Chen CL; Chou KJ; Lee PT; Chen YS; Chang TY; Hsu CY; Huang WC; Chung HM; Fang HC
    Exp Cell Res; 2010 Apr; 316(7):1109-18. PubMed ID: 20202468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor-β/Smad signalling in diabetic nephropathy.
    Lan HY
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):731-8. PubMed ID: 22211842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis.
    Peters H; Border WA; Noble NA
    Kidney Int; 2000 Apr; 57(4):1493-501. PubMed ID: 10760085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy.
    Chou JL; Chen LY; Lai HC; Chan MW
    Expert Opin Ther Targets; 2010 Nov; 14(11):1213-23. PubMed ID: 20925461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen attenuates cardiac fibroblasts activations through modulations of transforming growth factor-β and angiotensin II signaling.
    Chung CC; Hsu RC; Kao YH; Liou JP; Lu YY; Chen YJ
    Int J Cardiol; 2014 Sep; 176(2):386-93. PubMed ID: 25125004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor β induces expression of connective tissue growth factor in hepatic progenitor cells through Smad independent signaling.
    Ding ZY; Jin GN; Liang HF; Wang W; Chen WX; Datta PK; Zhang MZ; Zhang B; Chen XP
    Cell Signal; 2013 Oct; 25(10):1981-92. PubMed ID: 23727026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of tubular epithelial-mesenchymal transition in progressive kidney disease.
    Burns WC; Kantharidis P; Thomas MC
    Cells Tissues Organs; 2007; 185(1-3):222-31. PubMed ID: 17587828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SMAD inhibition attenuates epithelial to mesenchymal transition by primary keratinocytes in vitro.
    O'Kane D; Jackson MV; Kissenpfennig A; Spence S; Damkat-Thomas L; Tolland JP; Smyth AE; Denton CP; Stuart Elborn J; McAuley DF; O'Kane CM
    Exp Dermatol; 2014 Jul; 23(7):497-503. PubMed ID: 24848428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of TGF-beta/Smad signaling pathway on lung myofibroblast differentiation.
    Gu L; Zhu YJ; Yang X; Guo ZJ; Xu WB; Tian XL
    Acta Pharmacol Sin; 2007 Mar; 28(3):382-91. PubMed ID: 17303001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.